The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.Clinical-stage biotech AnaptysBio (ANAB -1.30%) has recently been something of a standout, at least on the stock exchange. According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's share price had increased by nearly 10% week to date as of Friday before market open. Although there was little market-moving dir ...